HIV-M.tb co-infection has been the most challenging concern in the efforts to scale up antiretroviral therapy (ART) because a subset of patients develop a condition called TB-IRIS, which arises as M.tb-specific CD4+ T cells re-emerge after ART initiation (1). The gene discussed is CD4; the disease is tuberculosis.